Liver function may affect prostate cancer drug levels
NCT ID NCT06860243
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study looked at how the experimental prostate cancer drug opevesostat (MK-5684) moves through the body in men with moderate liver impairment compared to healthy men. Sixteen male participants received a single dose, and researchers measured drug levels over time. The goal was to understand if liver problems change how the drug is processed, which helps guide safe dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami ( Site 0002)
Miami, Florida, 33172, United States
-
Texas Liver Institute ( Site 0001)
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.